Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented preclinical findings at the Society for Immunotherapy of Cancer Annual Meeting, highlighting the potential of combining selective adenosine A2B and A2A antagonists with cancer vaccines to enhance immune response against tumors [1][2][3] Company Overview - AlphaTON Capital is focused on building a strategic reserve of TON tokens and developing the Telegram ecosystem, providing institutional-grade exposure to the TON ecosystem while maintaining governance standards of a Nasdaq-listed company [7][8] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists targeting A2B and A2A receptors to overcome immune suppression in oncology, with a lead program TT-4 aimed at mesothelioma [10] Clinical Development - The clinical program for TT-4 (A2B receptor antagonist) is preparing for first-patient dosing in Q1 2026, while TT-10 (A2A receptor antagonist) is currently in Phase 1 dose escalation for advanced solid tumors [6] - Preclinical studies demonstrated that the combination of TT-4 and TT-10 with therapeutic vaccines resulted in significant tumor growth suppression and improved survival in mouse models [2][3] Research Collaboration - The collaboration with the National Cancer Institute reflects a multi-year effort to explore the synergistic effects of adenosine receptor antagonists and cancer vaccines, aiming to translate these findings into human applications [3][4]

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented preclinical findings at the Society for Immunotherapy of Cancer Annual Meeting, highlighting the potential of combining selective adenosine A2B and A2A antagonists with cancer vaccines to enhance immune response [1][2][3] Research Findings - The studies conducted by the National Cancer Institute demonstrated that the combination of TT-4 (A2B antagonist) and TT-10 (A2A antagonist) with therapeutic vaccines resulted in significant tumor growth suppression and improved survival rates in mouse models [2] - In the TC1 lung cancer model, the triple combination of TT-4, TT-10, and an E7 peptide vaccine led to complete tumor regression in several mice, showcasing the potential for these treatments to translate to human applications [2] Clinical Development Status - TT-4 is an IND-enabled program with mesothelioma as the lead indication, preparing for first-patient dosing in Q1 2026 [4] - TT-10 is currently undergoing Phase 1 dose escalation trials in patients with advanced solid tumors [4] Strategic Goals - The collaboration with NCI reflects a long-term effort to enhance vaccine-driven immunity through the co-administration of selective receptor antagonists [3] - AlphaTON aims to leverage these preclinical data to guide capital deployment and partnerships for advancing TT-4 and TT-10 in clinical settings [3][10]